Earlier lines of cilta-cel linked to better immune fitness in myeloma
Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai,
Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai,
Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, discusses the biggest highlights from
In this video, the group discusses unmet needs in large cell lymphoma and novel agents, including the CELLMod golcadomide.
In patients with polycythemia vera receiving standard of care therapy, treatment with rusfertide continued to yield a statistically significant reduction in the mean
Epcoritamab in combination with rituximab and lenalidomide has the potential to be the new standard of care in patients with second-line follicular lymphoma,
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with significantly higher rates of severe toxicity following B-cell maturation antigen (BCMA)-targeted CAR T-cell
In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at
SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical
2027-2028 SOHO President-elect Valeria Santini, MD, grew up in Florence, where she says the city’s beauty, history, and art shaped her entire outlook
Despite ALL treatment progress, patients still need safer, more effective options Novel agents have transformed outcomes for patients with relapsed or refractory acute